IceCure Medical Ltd. (NASDAQ:ICCM - Get Free Report)'s stock price traded up 0.8% on Wednesday . The company traded as high as $0.98 and last traded at $0.95. 125,625 shares were traded during mid-day trading, a decline of 73% from the average session volume of 469,709 shares. The stock had previously closed at $0.94.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a "buy" rating and set a $2.50 price target on shares of IceCure Medical in a research report on Thursday, May 29th.
View Our Latest Analysis on ICCM
IceCure Medical Stock Performance
The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.48 and a current ratio of 1.89. The company has a market cap of $52.73 million, a PE ratio of -3.39 and a beta of 0.33. The company's 50 day moving average price is $1.07 and its 200-day moving average price is $1.17.
IceCure Medical (NASDAQ:ICCM - Get Free Report) last announced its quarterly earnings data on Wednesday, May 28th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.02. The business had revenue of $0.73 million during the quarter, compared to analyst estimates of $0.75 million. IceCure Medical had a negative return on equity of 182.26% and a negative net margin of 467.37%. During the same period in the prior year, the company earned ($0.08) earnings per share. Equities research analysts anticipate that IceCure Medical Ltd. will post -0.28 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in IceCure Medical stock. XTX Topco Ltd raised its holdings in shares of IceCure Medical Ltd. (NASDAQ:ICCM - Free Report) by 123.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 58,866 shares of the company's stock after purchasing an additional 32,555 shares during the quarter. XTX Topco Ltd owned approximately 0.11% of IceCure Medical worth $65,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 0.62% of the company's stock.
About IceCure Medical
(
Get Free Report)
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider IceCure Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IceCure Medical wasn't on the list.
While IceCure Medical currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
